home > news > detailed info

PHASTAR Names Chris Schoonmaker as Chief Operations Officer


London, UK and Durham, NC - June 29, 2022 – PHASTAR, a global specialist biometrics contract research organization (CRO) offering industry leading data management, data science, statistical consulting, and clinical trial reporting services, today announces that Chris Schoonmaker has joined the company as Chief Operations Officer. Chris will direct PHASTAR’s operational strategy with a key focus on ensuring quality deliverables and providing a positive customer experience.

Andrew MacGarvey, PHASTAR’s Chief Executive Officer said “I am delighted to welcome Chris to the team. His experience running global operations coupled with his reputation for excellent customer service will be invaluable as we continue to scale the business. He is joining a fantastic management team and will help us execute against our mission to be the provider of choice for biometrics services around the world, and to be the employer of choice for biometrics professionals."

Chris has worked in the clinical trial and health care space for over 25 years and has held several senior leadership roles, including oversight of biometric operations as well as managing customer relationships related to strategic accounts. The majority of his career has been with CROs, where he has developed effective operational strategies coinciding with business growth. Throughout his career, Chris has been a statistical lead for hundreds of clinical studies, served as a voting member on data monitoring committees, provided statistical consultation, and guided the statistical strategy for dozens of regulatory submissions. Chris received his Master of Public Health in Epidemiology and Biostatics from Boston University.

For further information on PHASTAR contact
phone +44 (0)20 7183 7062
email Unit 2, 2A Bollo Ln, Chiswick, London W4 5LE
Print this page
Send to a friend
News and Press Releases

Janssen Marks First Approval Worldwide for TECVAYLI®▼(teclistamab) With EC Authorisation of Bispecific Antibody for the Treatment of Patients With Multiple Myeloma

BEERSE, BELGIUM, 24 August 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted conditional marketing authorisation (CMA) of TECVAYLI®▼ (teclistamab) as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). Patients must have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.1 Today’s milestone marks the first approval worldwide for teclistamab, a bispecific antibody that redirects CD3-positive T-cells to B-cell maturation antigen (BCMA)-expressing myeloma cells to induce the killing of tumour cells.1
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement